Sangamo Biosciences (SGMO) Stock Forecast & Price Target

Compare

2,556 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SGMO Analyst Ratings

Moderate Buy

1 Buy

2 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Sangamo

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SGMO Stock 12 Month Forecast

Average Price Target

$4.33

▲(862.22% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Sangamo Biosciences in the last 3 months. The average price target is $4.33 with a high forecast of $10.00 and a low forecast of $1.00. The average price target represents a 862.22% change from the last price of $0.45.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.6,1.323076923076923,2.046153846153846,2.769230769230769,3.4923076923076923,4.2153846153846155,4.938461538461538,5.661538461538461,6.384615384615384,7.107692307692307,7.8307692307692305,8.553846153846154,9.276923076923076,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.6,0.8869230769230769,1.1738461538461538,1.4607692307692308,1.7476923076923079,2.034615384615385,2.3215384615384616,2.6084615384615386,2.8953846153846157,3.1823076923076927,3.46923076923077,3.7561538461538464,4.0430769230769235,{"y":4.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.6,0.6307692307692307,0.6615384615384615,0.6923076923076923,0.7230769230769231,0.7538461538461538,0.7846153846153846,0.8153846153846154,0.8461538461538461,0.8769230769230769,0.9076923076923077,0.9384615384615385,0.9692307692307692,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.57,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.47,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.56,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.67,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$10.00

Average Price Target$4.33

Lowest Price Target$1.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick Trucchio

H.C. Wainwright

$10

Buy

2122.22%

Upside

Reiterated

11/21/25

Buy Rating for Sangamo Biosciences Driven by FDA Milestone and Promising Trial Results for ST-920 Gene TherapyValuation and Risks. We assess Sangamo using a discounted cash flow (DCF)-based and sum-of-the-parts (SOTP)-based methodology. We assign probability of success to isaralgagene civaparvovec (SB-920) in Fabry disease of 85%. We model a build in continued milestone payments and revenues tied to Sangamo's SIFTER / ZFP platforms starting in 2025, leading to a moderate present value. We include a gross capital raise of $150 million in 2026E, which could dilute existing shareholders. We employ a 12% discount rate and a terminal multiple of 6.0x.

Gena Wang

Barclays

$5→$1

Hold

122.22%

Upside

Downgraded

11/07/25

Sangamo Biosciences (SGMO) was downgraded to a Hold Rating at Barclays

Luca Issi

RBC Capital

Hold

344.44%

Upside

Reiterated

11/06/25

RBC Capital Remains a Hold on Sangamo Biosciences (SGMO)

Ritu Baral

TD Cowen

―

Buy

―

Reiterated

08/11/25

Sangamo Biosciences: Strategic Positioning and Growth Potential Drive Buy RatingWe estimate pro forma current cash of ~$29M may bridge OpEx into 4Q25. SGMO continues to engage in partnership talks for BLA-ready giro in HemeA. Mgmt maintained guidance for FY25 GAAP FY25 non-GAAP OpEx of $124- 145M. SGMO will present additional Ph1/2 '920 Fabry data at ICIEM (Sept 2 - Sept 6; Kyoto). First Ph1/2 iSFN data is on track for 4Q26.

Yanan Zhu

Wells Fargo

Hold

344.44%

Upside

Reiterated

06/25/25

Cautious Optimism for Sangamo Biosciences Amid Promising Fabry Program Data and Ongoing Business Developments

Maury Raycroft

Jefferies

$2→$1.5

Buy

233.33%

Upside

Reiterated

05/13/25

Sangamo BioSciences (SGMO) PT Lowered to $1.50 at JefferiesJefferies analyst Maury Raycroft lowered the price target on Sangamo BioSciences (NASDAQ: SGMO) to $1.50 (from $2.00) while maintaining a Buy rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick Trucchio

H.C. Wainwright

$10

Buy

2122.22%

Upside

Reiterated

11/21/25

Gena Wang

Barclays

$5→$1

Hold

122.22%

Upside

Downgraded

11/07/25

Sangamo Biosciences (SGMO) was downgraded to a Hold Rating at Barclays

Luca Issi

RBC Capital

Hold

344.44%

Upside

Reiterated

11/06/25

RBC Capital Remains a Hold on Sangamo Biosciences (SGMO)

Ritu Baral

TD Cowen

―

Buy

―

Reiterated

08/11/25

Yanan Zhu

Wells Fargo

Hold

344.44%

Upside

Reiterated

06/25/25

Cautious Optimism for Sangamo Biosciences Amid Promising Fabry Program Data and Ongoing Business Developments

Maury Raycroft

Jefferies

$2→$1.5

Buy

233.33%

Upside

Reiterated

05/13/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sangamo Biosciences

1 Month

xxx

Success Rate

8/17 ratings generated profit

Average Return

-3.68%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 47.06% of your transactions generating a profit, with an average return of -3.68% per trade.

3 Months

xxx

Success Rate

8/17 ratings generated profit

Average Return

+7.82%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 47.06% of your transactions generating a profit, with an average return of +7.82% per trade.

1 Year

Patrick TrucchioH.C. Wainwright

Success Rate

6/20 ratings generated profit

Average Return

+23.00%

reiterated a buy rating 30 days ago

Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of +23.00% per trade.

2 Years

xxx

Success Rate

2/17 ratings generated profit

Average Return

-36.70%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 11.76% of your transactions generating a profit, with an average return of -36.70% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SGMO Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SGMO has received 3 Buy Ratings, 12 Hold Ratings, and 2 Sell Ratings. SGMO average Analyst price target in the past 3 months is 4.33.

Each month's total comprises the sum of three months' worth of ratings.

SGMO Financial Forecast

SGMO Earnings Forecast

Next quarter’s earnings estimate for SGMO is -$0.01 with a range of -$0.11 to $0.18. The previous quarter’s EPS was -$0.11. SGMO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year SGMO has Performed in-line its overall industry.

SGMO Sales Forecast

Next quarter’s sales forecast for SGMO is $40.23M with a range of $10.00M to $100.00M. The previous quarter’s sales results were $581.00K. SGMO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year SGMO has Performed in-line its overall industry.

SGMO Stock Forecast FAQ

What is SGMO’s average 12-month price target, according to analysts?

Based on analyst ratings, Sangamo Biosciences’s 12-month average price target is 4.33.

What is SGMO’s upside potential, based on the analysts’ average price target?

Sangamo Biosciences has 862.22% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SGMO a Buy, Sell or Hold?

Sangamo Biosciences has a consensus rating of Moderate Buy which is based on 1 buy ratings, 2 hold ratings and 0 sell ratings.

What is Sangamo Biosciences’s price target?

The average price target for Sangamo Biosciences is 4.33. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $10.00 ,the lowest forecast is $1.00. The average price target represents 862.22% Increase from the current price of $0.45.

What do analysts say about Sangamo Biosciences?

Sangamo Biosciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of SGMO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Sangamo Biosciences (SGMO) Stock Forecast & Price Target

SGMO Analyst Ratings

SGMO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sangamo Biosciences

SGMO Analyst Recommendation Trends

SGMO Financial Forecast

SGMO Earnings Forecast

SGMO Sales Forecast

SGMO Stock Forecast FAQ

Detailed List of Analyst Forecasts